Literature DB >> 16984726

Preoperative plasma transcript AA454543 level is an independent prognostic factor for hepatocellular carcinoma after partial hepatectomy.

Siu Tim Cheung1, Chi Leung Liu, Jeremy P H Chow, Yuk Ting Lee, Ying Chi Ip, Jenny C Y Ho, Sheung Tat Fan.   

Abstract

BACKGROUND: We have previously reported that tissue expression levels of transcript AA454543 in hepatocellular carcinoma (HCC) are significantly higher than those of normal livers, livers with cirrhosis, and livers with hepatitis. In addition, a higher level of transcript AA454543 in tumor tissues is associated with poor prognosis. We aim to examine whether quantitative measurement of preoperative plasma transcript AA454543 can provide similar prognostic information. PATIENTS AND METHODS: Blood samples were obtained from 84 HCC patients before surgery. Real-time quantitative reverse transcription-polymerase chain reaction, using TaqMan system, was employed to measure plasma transcript AA454543 and alpha-fetoprotein (AFP) RNA levels. We assessed their prediction power in prognosis using univariate and multivariate analyses.
RESULTS: High plasma transcript AA454543 RNA levels were associated with poor overall survival (log-rank test, P < .01). Patients with different plasma AFP RNA levels revealed no difference in overall survival (log-rank test, P = .88). By multivariate Cox regression analysis, plasma transcript AA454543 RNA level (hazard ratio = 4.8, P < .01) and tumor stage (hazard ratio = 1.7, P < .01) were determined to be independent risk factors for the prediction of overall survival.
CONCLUSION: Preoperative plasma transcript AA454543 RNA level can provide prognostic information for HCC patients receiving curative partial hepatectomy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16984726      PMCID: PMC1584293          DOI: 10.1593/neo.06181

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  35 in total

Review 1.  Circulating DNA. What we know and what we need to learn.

Authors:  D Sidransky
Journal:  Ann N Y Acad Sci       Date:  2000-04       Impact factor: 5.691

Review 2.  Cellular- versus extracellular-based assays. Comparing utility in DNA and RNA molecular marker assessment.

Authors:  M S Kopreski; C D Gocke
Journal:  Ann N Y Acad Sci       Date:  2000-04       Impact factor: 5.691

3.  Extracellular tyrosinase mRNA within apoptotic bodies is protected from degradation in human serum.

Authors:  D O Hasselmann; G Rappl; W Tilgen; U Reinhold
Journal:  Clin Chem       Date:  2001-08       Impact factor: 8.327

Review 4.  Circulating tumorous cells in patients with hepatocellular carcinoma. Clinical impact and future directions.

Authors:  P Paterlini-Bréchot; G Vona; C Bréchot
Journal:  Semin Cancer Biol       Date:  2000-06       Impact factor: 15.707

5.  Hematogenous dissemination of hepatocytes and tumor cells after surgical resection of hepatocellular carcinoma: a quantitative analysis.

Authors:  I H Wong; W Y Lau; T Leung; W Yeo; P J Johnson
Journal:  Clin Cancer Res       Date:  1999-12       Impact factor: 12.531

6.  Reporting recommendations for tumor marker prognostic studies.

Authors:  Lisa M McShane; Douglas G Altman; Willi Sauerbrei; Sheila E Taube; Massimo Gion; Gary M Clark
Journal:  J Clin Oncol       Date:  2005-09-19       Impact factor: 44.544

7.  DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells.

Authors:  S Jahr; H Hentze; S Englisch; D Hardt; F O Fackelmayer; R D Hesch; R Knippers
Journal:  Cancer Res       Date:  2001-02-15       Impact factor: 12.701

8.  alpha-Fetoprotein mRNA in the circulation as a predictor of postsurgical recurrence of hepatocellular carcinoma: a prospective study.

Authors:  Masayoshi Ijichi; Tadatoshi Takayama; Masayuki Matsumura; Yasushi Shiratori; Masao Omata; Masatoshi Makuuchi
Journal:  Hepatology       Date:  2002-04       Impact factor: 17.425

9.  Detection of epithelial messenger RNA in the plasma of breast cancer patients is associated with poor prognosis tumor characteristics.

Authors:  J M Silva; G Dominguez; J Silva; J M Garcia; A Sanchez; O Rodriguez; M Provencio; P España; F Bonilla
Journal:  Clin Cancer Res       Date:  2001-09       Impact factor: 12.531

10.  Telomerase RNA as a detection marker in the serum of breast cancer patients.

Authors:  X Q Chen; H Bonnefoi; M F Pelte; J Lyautey; C Lederrey; S Movarekhi; P Schaeffer; H E Mulcahy; P Meyer; M Stroun; P Anker
Journal:  Clin Cancer Res       Date:  2000-10       Impact factor: 12.531

View more
  4 in total

1.  GNAS1 T393C polymorphism is associated with clinical course in patients with intrahepatic cholangiocarcinoma.

Authors:  Klaus J Schmitz; Hauke Lang; Ulrich H Frey; Georgios C Sotiropoulos; Jeremias Wohlschlaeger; Henning Reis; Atsushi Takeda; Winfried Siffert; Kurt W Schmid; Hideo A Baba
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

2.  Neoplasia: the second decade.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

3.  Down-regulation of retinol binding protein 5 is associated with aggressive tumor features in hepatocellular carcinoma.

Authors:  Jenny C Y Ho; Siu Tim Cheung; Wing Sem Poon; Yuk Ting Lee; Irene O L Ng; Sheung Tat Fan
Journal:  J Cancer Res Clin Oncol       Date:  2007-05-12       Impact factor: 4.553

4.  Circulating tumor cells measurements in hepatocellular carcinoma.

Authors:  Franck Chiappini
Journal:  Int J Hepatol       Date:  2012-05-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.